O-GlcNAc Biomarker Detection for Early Diabetes Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing diabetes, particularly pre-diabetes, are inadequate as they fail to accurately reflect daily glycemic patterns and are insensitive for early detection, leading to delayed intervention and potential lifelong insulin dependence.
Innovation Solution
A method involving the use of O-GlcNAcylation levels, where a reagent binds to O-linked N-acetyl-glucosamine (O-GlcNAc) in a sample, and comparing it to normal levels, with an antibody that can be detectably labeled, to determine if a subject is at risk of having pre-diabetes or diabetes, and monitoring therapeutic regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods (FPG, OGTT, HbA1c) are used to diagnose diabetes, then the diagnosis can be made with existing standardized tests, but the sensitivity for early detection of pre-diabetes is insufficient
Solution Approach 1:
The patent changes the measurement parameter from traditional glucose metrics (FPG, OGTT, HbA1c) to O-GlcNAc levels on proteins. This parameter change enables detection of pre-diabetic states with higher sensitivity while maintaining diagnostic reliability, as O-GlcNAc modification reflects cellular glucose exposure more accurately than blood glucose measurements alone.
Solution Approach 2:
The patent uses O-GlcNAc modified proteins as an intermediary marker to detect pre-diabetic states. Instead of directly measuring glucose or HbA1c, the method measures O-GlcNAc levels on specific proteins (such as hemoglobin or other blood proteins), which serve as intermediaries that reflect chronic glucose exposure and cellular glycemic patterns more sensitively.
2Ease of operation
If Fasting Plasma Glucose (FPG) measurement is used, then the test is simple and standardized, but it reflects only post-absorptive balance and not daily glycemic patterns
Solution Approach 1:
The patent applies the principle of continuity by measuring O-GlcNAc modification on proteins that reflect continuous glucose exposure over time. Unlike FPG which captures a single moment, O-GlcNAc levels on proteins integrate glycemic information continuously, preserving daily glycemic pattern information while maintaining test simplicity through a single blood draw.
Solution Approach 2:
The patent uses O-GlcNAc modified proteins as intermediaries that capture and store glycemic pattern information. These modified proteins serve as biological records of glucose exposure, allowing the simple FPG test format to yield richer information about daily glycemic patterns through the intermediary marker.
3Reliability
If Hemoglobin Alc (HbA1c) is used for diagnosis, then the test is specific for diabetes, but it is insensitive for detecting pre-diabetics and early-onset diabetes
Solution Approach 1:
The patent applies local quality by focusing on specific O-GlcNAc modified proteins rather than global HbA1c measurement. By selecting specific proteins with O-GlcNAc modifications that are particularly sensitive to early glycemic changes, the method maintains the specificity of targeted measurement while achieving higher sensitivity for pre-diabetes detection compared to general HbA1c.
Solution Approach 2:
The patent changes the measurement parameter from HbA1c (which measures glycation) to O-GlcNAc levels (which measure enzymatic glycosylation). This parameter change increases detection sensitivity for pre-diabetic states while maintaining diagnostic specificity, as O-GlcNAc modification is more sensitive to early glucose exposure changes than non-enzymatic glycation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for early identification of pre-diabetic states by measuring O-GlcNAcylation levels in blood samples, providing a more accurate and sensitive diagnosis compared to existing methods, enabling timely intervention and potentially avoiding insulin dependence.
Implementation Method 1
contacting a test sample from the subject with a reagent that binds to O-linked N-acetyl-glucosamine (O-GlcNAc)
Data Source
AI summary
The present invention is based on the discovery that hexosamine, and in particular the dynamic O-GlcNAcylation of proteins (modification of proteins by the sugar N-acetylglucosamine) both causes insulin-resistance (a hallmark of type II diabetes) and is responsible for glucose toxicity in the disease. Accordingly, the invention provides methods of diagnosing a subject as having or at risk of having pre-diabetes or diabetes. Also provided are methods of characterizing hyperglycemia in a subject, methods of identifying a protein as being associated with hyperglycemia, and kits for detecting pre-diabetes or diabetes.